Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Gutzmer, Ralf Stroyakovskiy, Daniil Gogas, Helen Robert, Caroline Lewis, Karl Protsenko, Svetlana Pereira, Rodrigo P Eigentler, Thomas Rutkowski, Piotr Demidov, Lev Manikhas, Georgy Moiseevich Yan, Yibing Huang, Kuan-Chieh Uyei, Anne McNally, Virginia McArthur, Grant A Ascierto, Paolo A